Psychometric Evaluation of the Migraine-Specific Quality of Life Questionnaire (MSQ v2.1) Using Data From Phase 3 Clinical Trials in Patients With Chronic Migraine (CM) and Episodic Migraine (EM) (P8-12.007)
Jonathan Stokes(Adelphi Laboratory Center), Pranav Gandhi(AbbVie (United States)), David W. Dodick(New York Academy of Medicine), Stuart Yarr, Yulia Savva(Ithaka Harbors), Lauren Nelson(RTI Health Solutions), Richard Lipton(Albert Einstein College of Medicine), Diane Whalley(RTI Health Solutions), Heather L. Gelhorn(Ithaka Harbors)
Cited by 0
Related Papers
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease
|Annals of Neurology|1999|890
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
|The Lancet|2019|472
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
|British Journal of Dermatology|2019|384